Programme Overview

Date	Event	Timing
Wednesday, June 3 Thursday, June 4 Thursday, June 4 Friday, June 5 Saturday, June 6 Sunday, June 7 Monday, June 8	Management Committee meeting Continuous Education Programme RIWC 2020 and NOK 2020 Shared Welcoming Ceremony Retina International Conference Retina International Conference Retina International General Assembly Incoming MC meeting (tentative)	TBA 09:00 – 16:00 TBA See programme below See programme below TBA TBA

Youth Programme Overview

Youth Programme Outline

Youth Programme Practical Information

Date	Event	Venue
Tuesday, June 2 Wednesday, June 3 Thursday, June 4 Friday, June 5 Saturday, June 6 Sunday, June 7	Arrival in Iceland Youth conference Horse Riding Tour / Workshop / Welcome Ceremony Lecture / Congress / Concert Retina Congress / Gala Dinner Optional activities	Studenthostel Hamrahlíð 17 / Downtown Íshestar / Hamrahlíð 17 / Eldborg, Harpa Hamrahlíð 17 / Harpa Harpa concert hall / Kolabrautin x

Conference Programme Outline

Programme Outline (PDF)


Thursday June 4th
RIWC 2020				View NOK 2020 Programme
Hall	Norðurljós	Björtuloft	Eldborg
08:00-08:30
08:30-10:00
10:00-10:30
10:30-11:00
11:00-12:00
12:00-13:30
13:30-15:00
15:00-15:30
15:30-17:00
17:00-17:30
17:30-19:00			17:00 – 19:00 Welcoming ceremony.
17:30-18:30			K.1.1.Key note: The development of a bioelectronic implant for sight restoration for retinal degenerations. Prof. Mark S. Humayun University of Southern California, LA, USA


Friday June 5th
RIWC 2020			View NOK 2020 Programme
Hall	Norðurljós	Björtuloft
07:40-08:20
08:30-10:00	P.2.1 Age related macular Degeneration Moderator: Dr. Øystein Kalsnes Jørstad, Oslo University	L.2.1 Retinal degenerations. Clinical aspects. Moderator: Dr. Prof. Elise Heon, The Hospital for Sick Children, Toronto, Canada
	08:30 - 08:50: A systems level investigation on AMD: Insights from the European EYERISK project Speaker: Professor Marius Ueffing, Centre for Ophthalmology, University Medical Center, Tuebingen, Germany	08:30 – 08:50: Clinical aspects of IRD Speaker: Prof. Dr. Elise Heon The Hospital for Sick Children, Toronto, Canada
	08:50 - 09:05: AMD research at Oslo University Hospital: from LUCAS to compounding pharmacy Speaker: Professor Morten Carstens Moe, Oslo University Hospital, Oslo, Norway	08:50 - 09:10: Clinical aspects of inherited macular degenerations. Speaker: Dr. Line Kessel, Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark.
	09.05.- 09:15: Off-label use of Avastin: Scandinavian disparities Speaker: Tomas Bro, MD, PhD, Höglandssjukhuset, Eksjö, Sweden	09:10 - 09:30 Usher syndrome and similar syndromic forms of IRD. Speaker: prof. Dr. Hélène Dollfus, CARGO, Hôpitaux Universitaires de Strasbourg, France
	09:15-09:25: The risk of extending AMD treatment Speaker: David Epstein, MD, PhD. Sankt Erik Eye Hospital, Karolinska Institute, Stockholm, Sweden
	09:25 - 09:35 The Swedish Macula Register Speaker: Inger Westborg, MD, PhD., Uppsala University Hospital, Uppsala, Sweden
	09:35 - 09:50 AMD Epidemiology and Genetics. What is important! Speaker: Prof. emeritus Friðbert Jónasson, University of Iceland, Iceland:	09:30 - 09:50: The socio-economic impact of IRDs Speaker: Dr. Orla Galvin, Retina International, Dublin, Ireland
	09:50 - 10:00: QnA	09:50 – 10:00 QnA.
10:00-10:30	Coffee break
10:30-11:30	P.2.2 Assessment of Endpoints in clinical studies. Moderators Dr. Cecilie Bredrup, Bergen, Norway and Prof. Sten Kjellström, Lund, Sweden.	L.2.2 Retinal degenerations - the genetics. Moderator: Prof. Jón Jóhannes Jónsson, national University Hospital, Reykjavík, Iceland.
	10:30 – 10:50: How to measure the effects of gene therapy on meaningful vision for patients Speaker: Prof. Michael Larsen Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark:	10:30 – 10:50: Pattern of inheritance - easy to understand. Speaker: Dr. Eirný Þórólfsdóttir National University Hospital, Reykjavík, Iceland.
	10:50 – 11:10 Paediatric specificities in trials Speaker: Prof. Dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada	10:50 – 11:10: Understanding the results - a difficult task. Speaker: Prof. Jón Johannes Jónsson, national University Hospital, Reykjavík, Iceland.
	11:10 – 11:30: Developing Patient Relevant Outcomes in Gene Therapy Trials: The Novel Functional Vision Endpoint, the Multi-luminance Mobility Test (MLMT) Speaker: Dr. Daniel Chung, DO, MA, Spark Therapeutics, Philadelphia, USA	11:10 – 11:20 Lessons from Iceland on the diversity of genetic causes. Speaker: Daníel Þorsteinsson
		11:20 – 11:30: Accessing Genetic Testing for IRDs: The Patient Perspective. Speaker: Avril Daly, Retina International, Dublin, Ireland
11:30-12:00	K.2.1 Keynote: Scientific results, a rollercoaster between hope and deception Speaker: Christina Fasser, president of Retina International, Zurich (Switzerland)
12:00-13:30	Lunch
13:30-14:00	K.2.2 Keynote: Phenotyping and Genotyping in inherited retinal diseases. Speaker: Prof. Bart Leroy, University of Ghent, Gent, Belgium
14:00-15:00	P.2.3 Phenotyping and Genotyping in IRD. Moderators: Josephine Prener Holta	L.2.3 Basics of stem cell and gene-based therapies. Moderator: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA
	14:00 – 14:10: Natural history and clinical characterization of patients with retinitis pigmentosa caused by mutations in the PRPF31 gene Speaker: Dr. Kristian Lisbjerg, Copenhagen University Hospital, Denmark	14:00- 14:20 Overview of on-going clinical trials with stem cells Speaker: Prof. Goran Petrovski
	14:10 – 14:20: Genetic basis and phenotypic characterization of Danish patients with Achromatopsia. Speaker: Dr. Mette K.G. Andersen, Copenhagen University Hospital, Rigshospitalet-Glostrup, Copenhagen, Denmark	14:20 – 14;35 Stem cell trial on Retinitis pigmentosa. Speaker: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA
	14:20 – 14:30 Whole exome sequencing in the diagnosis of hereditary retinal disorders: A clinical perspective Speaker: Prof. Ragnhild janson Wives tad, Hauk eland University Hospital, Norway	14:35 – 14:50 Clinical trial in opto-genetics. Speaker: Prof. Isabelle Audo, INSERM, Paris, France
	14:30 – 14:50 ERN-EYE a booster for patients care and research for Rare Eye Diseases in Europe Speaker: prof. Dr. Hélène Dollfus, CARGO, Hôpitaux Universitaires de Strasbourg, France:	14:50 – 15:00 How to discriminate between real treatments offers and quacks. Speaker: Martin Smedstad Oslo, Norway.
	14:50 – 15:00 QnA
15:00-15:30	Coffee break
15:30-16:00	K.2.3 Keynote: Innovations in Ophthalmology. Prof. Eugene De Juan University of California, San Francisco, USA.
16:00-17:00	P.2.4. Innovations in Ophthalmology Moderators: Christina Fasser and Prof. Einar Stefánsson.	L.2.4 Rehabilitation and mobility training. Moderators: Vala Jóna Garðarsdóttir and Rosa María Hjörvar Iceland.
	Speakers: Dr. Sabri Markabi, MD Senior vice president of Research and Development and Chief Medical Officer of Alcon Laboratories, Inc., a subsidiary of Alcon, Inc., the world’s largest eye care company. Prof. Einar Stefánsson, National University Hospital in Iceland. Kathrine A. High, Emeritus co-founder, president and chief scientific officer of Spark. To be confirmed.	16:00 - 16:15: Mobility training and mobility tools Speaker: Vala Jóna Garðarsdóttir. National institute for the blind in Iceland.
		16:15 – 16:30 Reading with auxiliary aids Speaker: Rósa María Hjörvar. PhD student in Literature at the University of Iceland
		16:30-16:45: The assistive technology, aps etc. Speakers: Baldur Snær Sigurðsson and Hlynur Þór Agnarsson
		16:45 - 17:00: Coping with visual and hearing impairment: Speakers: Halla Dís Hallfreðsdóttir and Elín Yr. Hafdisardóttir Arnardóttir.


Saturday June 6th
RIWC 2020			View NOK 2020 Programme
Hall	Norðurljós	Björtuloft
08:00-08:30
08:30-10:00	P.3.1 Preparing for clinical trials in IRD. Moderator: Prof. Michael Larsen. Speakers to be confirmed	L.3.1 Clinical trials and therapies from a patient’s perspective. Moderator: Martin Smedstad, Oslo, Norway.
		08:30 – 08:50 Overview and future on on-going clinical trials Speaker Prof. Dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada
		08:50 – 09:10: RPE65 - the first gene therapy on the market Speaker: Dr. Daniel Chung, DO, MA, Spark Therapeutics, Philadelphia, USA.
		09:10 – 09:30 Oligonucleotides - a hope for all? Speaker: Prof. Bart Leroy, Gent University, Ghent, Belgium
		09:30 – 09:50 My personal experience with a clinical trial Speaker: to be confirmed.
10:00-10:30	Coffee break
10:30-12:00	P.3.2 Stem cells and cell-based therapies of retinal diseases. Moderator Dr. Goran Petrovski, Oslo, Norway.	L 3.2 Retina International - the global challenges Moderator: Kristinn Halldor Einarsson, Iceland
	10;30 – 10:45: Initiating a Phase I/IIa clinical trial for an autologous iPS cell therapy for macular degeneration: from bench-to-bedside. Speaker: Prof. Kapil Bharti (NIH/NEI), Bethesda, USA.	Speakers:Christina Fasser.Avril Daily. Other speakers to be confirmed.
	10:45 – 11:00 Towards stem cell-based therapies in retinal degenerations Speaker: Anders Kantar (Stockholm, Sweden
	11:00 – 11:30 Subretinal implantation of primary human RPE cells in minipig eyes. Speaker: Dr. Goran Petrovski, Oslo, Norway.
	11:30 – 12:00 Epigenetic characterization during differentiation from iPS to RPE cells in AMD. Speaker: Dr. Cristina Zibetti (Oslo, Norway)
12:00-13:30	Lunch
13:30-14:00	K.3.1 Keynote: Hope without Hype: Gene-based Therapies for Inherited Retinal Diseases Speaker: Prof. Artur Cideciyan, University of Pennsylvania, Philadelphia, USA.
14:00-15:00	P.3.3 Gene based therapies of retinal diseases. Moderator Eeva-Marja Sankila, MD, PhD, Helsinki University Hospital, Helsinki, Finland	L.3.4 Programme in islandic for the public. Moderator: Dr. Sigríður Másdóttir, Reykjavík, Iceland.
	14;00 – 14:15 CPK850 gene therapy in RLPB1 patients. Speaker: Prof. Anders Kantar, Karolinska Institute, Stockholm, Sweden
	14:15 – 14:30 Retinal gene therapy trials - investigators point of view Speaker: EevaMarja Sankila, MD, PhD, Helsinki University Hospital, Helsinki, Finland
	14:30 – 14:45 Retinal gene therapy in choroideremia patients - surgical aspects. Speaker: Prof. Illka Immonen, Helsinki University Hospital, Helsinki, Finland
	14:45 – 15:00 Gene therapy of Usher syndrome. Speaker: Prof. Isabelle Audo, Institute de la Vision, Paris, France
15:00-15:30	Coffee Break
15:30-17:00	K.3.3 What the future holds: Panel discussion (AMD, IRD, genetics, Innovation)
17:00-17:30	K.3.4 What have we learned? Speaker: Prof Emeritus Gerald G. Chader, Los Angeles, USA
17:30-18:00	Closing Ceremony